Page last updated: 2024-11-09

aeg 3482

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

AEG 3482: an antiapoptotic compound that induces expression of Hsp70; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID698112
CHEMBL ID19231
CHEBI ID114182
SCHEMBL ID2540289
MeSH IDM0499837

Synonyms (39)

Synonym
6-phenylimidazo[2,1-b][1,3,4]thiadiazole-2-sulfonamide
HMS3269J11
TIMTEC1_001442
OPREA1_698164
NCGC00167812-02
NCGC00167812-01
CHEBI:114182
HMS1538B12 ,
CHEMBL19231
63735-71-7
BCP9000242
aeg 3482
aeg-3482
unii-7ezf1a283n
imidazo(2,1-b)-1,3,4-thiadiazole-2-sulfonamide, 6-phenyl-
6-phenylimidazo(2,1-b)-1,3,4-thiadiazole-2-sulfonamide
7ezf1a283n ,
BRD-K77634909-001-01-9
CCG-221955
SCHEMBL2540289
6-phenyl-imidazo[2,1-b][1,3,4]thiadiazole-2-sulfonic acid amide
6-phenylimidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamide
AKOS024457221
imidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamide, 6-phenyl-
Q27195229
DTXSID80213176
aeg 3482, >=98% (hplc)
FT-0736105
HMS3677N15
BCP01890
HMS3413N15
BRD-K77634909-001-02-7
NCGC00167812-06
aeg3482
6-phenyl-imidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamide
MS-23975
HY-107599
CS-0028938
E98712
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
imidazolesA five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency33.55210.00798.23321,122.0200AID2546; AID2551
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID50177In vitro inhibition of carbonic anhydrase was determined using enzyme prepared from mouse erythrocytes1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Cerebrovasodilatation through selective inhibition of the enzyme carbonic anhydrase. 2. Imidazo[2,1-b]thiadiazole and imidazo[2,1-b]thiazolesulfonamides.
AID226919Anticonvulsant potency in mice relative to compound UK-12130 (ED50 of compound 24/compound)1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Cerebrovasodilatation through selective inhibition of the enzyme carbonic anhydrase. 2. Imidazo[2,1-b]thiadiazole and imidazo[2,1-b]thiazolesulfonamides.
AID131557Protective dose against maximal electroshock in mice after peroral administration1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Cerebrovasodilatation through selective inhibition of the enzyme carbonic anhydrase. 2. Imidazo[2,1-b]thiadiazole and imidazo[2,1-b]thiazolesulfonamides.
AID26085pKa of the compound was determined1980Journal of medicinal chemistry, Feb, Volume: 23, Issue:2
Cerebrovasodilatation through selective inhibition of the enzyme carbonic anhydrase. 2. Imidazo[2,1-b]thiadiazole and imidazo[2,1-b]thiazolesulfonamides.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (10.00)18.7374
1990's0 (0.00)18.2507
2000's2 (20.00)29.6817
2010's4 (40.00)24.3611
2020's3 (30.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.16

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.16 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.38 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.16)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]